Congenital Heart Disease Specialists play a crucial role in diagnosing and treating heart conditions that are present at birth. These specialists are trained to assess a wide range of heart defects, from simple to complex, ensuring early intervention to improve the overall prognosis. The primary focus of these specialists is to identify structural abnormalities in the heart that can affect its normal functioning. They work closely with other healthcare professionals to provide personalized care, utilizing advanced diagnostic tools such as echocardiograms, MRIs, and heart catheterizations. Their expertise allows them to create tailored treatment plans that can include medication, surgical intervention, or minimally invasive procedures, aimed at managing the condition effectively.
Beyond diagnosis and treatment, congenital heart disease specialists are instrumental in the long-term management of patients, guiding them through the challenges that come with living with a congenital condition. They provide ongoing monitoring and care to ensure the heart functions optimally throughout the patient's life. Many specialists work with multidisciplinary teams to ensure comprehensive care, addressing not only the physical aspects but also the emotional and psychological effects of congenital heart conditions. Their goal is to improve quality of life, provide support for families, and enable patients to lead as normal and active a life as possible, despite their heart condition.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India